KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Non-Current Deffered Revenue: 2010-2022

Historic Non-Current Deffered Revenue for Emergent BioSolutions (EBS) over the last 8 years, with Mar 2022 value amounting to $5.9 million.

  • Emergent BioSolutions' Non-Current Deffered Revenue fell 88.76% to $5.9 million in Q1 2022 from the same period last year, while for Mar 2022 it was $5.9 million, marking a year-over-year decrease of 88.76%. This contributed to the annual value of $4.7 million for FY2021, which is 91.53% down from last year.
  • As of Q1 2022, Emergent BioSolutions' Non-Current Deffered Revenue stood at $5.9 million, which was up 25.53% from $4.7 million recorded in Q4 2021.
  • Emergent BioSolutions' Non-Current Deffered Revenue's 5-year high stood at $85.6 million during Q4 2019, with a 5-year trough of $4.7 million in Q4 2021.
  • Over the past 3 years, Emergent BioSolutions' median Non-Current Deffered Revenue value was $52.5 million (recorded in 2021), while the average stood at $49.3 million.
  • In the last 5 years, Emergent BioSolutions' Non-Current Deffered Revenue spiked by 327.49% in 2018 and then crashed by 91.53% in 2021.
  • Quarterly analysis of 5 years shows Emergent BioSolutions' Non-Current Deffered Revenue stood at $62.5 million in 2018, then surged by 36.96% to $85.6 million in 2019, then slumped by 35.16% to $55.5 million in 2020, then plummeted by 91.53% to $4.7 million in 2021, then slumped by 88.76% to $5.9 million in 2022.
  • Its last three reported values are $5.9 million in Q1 2022, $4.7 million for Q4 2021, and $45.3 million during Q3 2021.